Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Depreciation (2016 - 2023)

Editas Medicine (EDIT) has disclosed Accumulated Depreciation for 8 consecutive years, with $21.5 million as the latest value for Q4 2022.

  • On a quarterly basis, Accumulated Depreciation rose 38.81% to $21.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was $21.5 million, a 38.81% increase, with the full-year FY2022 number at $21.5 million, up 38.81% from a year prior.
  • Accumulated Depreciation was $21.5 million for Q4 2022 at Editas Medicine, up from $17.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $21.5 million in Q4 2022 to a low of $5.1 million in Q1 2019.
  • A 5-year average of $10.9 million and a median of $9.9 million in 2020 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 75.78% in 2018, then increased 1.0% in 2019.
  • Editas Medicine's Accumulated Depreciation stood at $7.1 million in 2018, then rose by 1.0% to $7.2 million in 2019, then soared by 54.01% to $11.1 million in 2020, then soared by 39.77% to $15.5 million in 2021, then skyrocketed by 38.81% to $21.5 million in 2022.
  • Per Business Quant, the three most recent readings for EDIT's Accumulated Depreciation are $21.5 million (Q4 2022), $17.1 million (Q1 2022), and $15.5 million (Q4 2021).